Recent results from a pilot trial testing the ‘Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19’ (IMPACT-SIRIO 5; NCT04941105) demonstrate a survival benefit among adult patients [36]. Here, PCSK9 is linked to COVID-19.